Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Pfizer is playing catch-up in the GLP-1 weight-loss space. The drugmaker is getting closer and closer to key patent cliffs. Investors should also note that Pfizer's payout ratio is worryingly high.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results